Calidi Biotherapeutics(US:CLDI)2025-11-13 21:30Financial Performance - Calidi Biotherapeutics reported a net loss of $5.2 million for Q3 2025, compared to a net loss of $5.1 million in Q3 2024, with a total net loss attributable to shareholders increasing to $10.8 million due to a non-cash charge for deemed dividend on warrants[7]. - The net loss per share for Q3 2025 was $2.21, a significant decrease from $7.75 in the same period of 2024[8][19]. Expenses - Research and development expenses were $2.4 million in Q3 2025, up from $2.2 million in Q3 2024, while general and administrative expenses decreased to $2.7 million from $3.1 million year-over-year[8]. - Total current liabilities decreased to $5.2 million as of September 30, 2025, from $9.5 million as of December 31, 2024[17]. Cash and Funding - The company raised $6.9 million in gross proceeds through an underwritten public offering, increasing total gross proceeds raised in 2025 to $23.0 million[5][13]. - As of September 30, 2025, Calidi had approximately $10.4 million in cash, compared to $9.6 million as of December 31, 2024[9]. Product Development - The lead candidate, CLD-401, is advancing to clinical trials and aims to target non-small cell lung cancer and ovarian cancer[3][11]. - The RedTail platform demonstrated the ability to effectively express genetic medicines at tumor sites in preclinical models, with results presented at the Society of Immunotherapy for Cancer (SITC) meeting[6]. - The company established a new Scientific Advisory Board to support the development of CLD-401 and advance the RedTail platform for systemic delivery of targeted genetic medicine[5][6]. Assets - Total assets as of September 30, 2025, were $14.0 million, slightly down from $14.2 million at the end of 2024[17].